Skip to main
INMD

Inmode Ltd (INMD) Stock Forecast & Price Target

Inmode Ltd (INMD) Analyst Ratings

Based on 4 analyst ratings
Hold
Strong Buy 0%
Buy 25%
Hold 75%
Sell 0%
Strong Sell 0%

Bulls say

InMode Ltd demonstrated significant growth in 2Q25, selling 971 systems, contributing to a global installed base of approximately 28,855 units, with 12,347 units located in the U.S., marking a 3.4% increase from the previous quarter. The company also achieved an operating margin of 27.5%, surpassing prior estimates and reflecting a year-over-year improvement of 40 basis points. Moreover, the U.S. domestic sales reached $49.7 million, indicating a robust 9% growth compared to a decline in the previous quarter, underpinning the positive trajectory of the aesthetics market driven by rising consumer and physician interest.

Bears say

InMode Ltd is expected to experience a contraction in its margins, which, while currently among the highest in the med tech sector, signals potential challenges ahead. Furthermore, the company's earnings per share (EPS) growth is forecasted to lag behind revenue growth, indicating a weakening profitability outlook. Additionally, the bear case scenario predicts a revenue compound annual growth rate (CAGR) of less than 5% over the next few years due to slower growth from existing products and limited adoption of new offerings.

Inmode Ltd (INMD) has been analyzed by 4 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 25% recommend Buy, 75% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Inmode Ltd and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Inmode Ltd (INMD) Forecast

Analysts have given Inmode Ltd (INMD) a Hold based on their latest research and market trends.

According to 4 analysts, Inmode Ltd (INMD) has a Hold consensus rating as of Feb 4, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $16.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $16.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Inmode Ltd (INMD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.